Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
- Manchester University to research the impact of CO on babies - 29th August 2025
- Starvation major cause for A&E admissions - 29th August 2025
- New Monoclonal Antibody Targets Deadly Sepsis - 22nd August 2025